Water Island Capital LLC grew its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 15.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 366,648 shares of the specialty pharmaceutical company’s stock after acquiring an additional 48,130 shares during the quarter. Water Island Capital LLC’s holdings in Paratek Pharmaceuticals were worth $1,965,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in PRTK. BNP Paribas Arbitrage SA purchased a new stake in shares of Paratek Pharmaceuticals during the 1st quarter valued at about $36,000. Hsbc Holdings PLC purchased a new stake in shares of Paratek Pharmaceuticals during the 4th quarter valued at about $59,000. Annex Advisory Services LLC boosted its holdings in shares of Paratek Pharmaceuticals by 15.3% during the 4th quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,000 shares during the last quarter. Stifel Financial Corp purchased a new stake in shares of Paratek Pharmaceuticals during the 4th quarter valued at about $90,000. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Paratek Pharmaceuticals by 15.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,867 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 2,500 shares during the last quarter. 74.27% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:PRTK traded up $0.07 during trading on Wednesday, hitting $4.81. The company’s stock had a trading volume of 5,737 shares, compared to its average volume of 261,938. Paratek Pharmaceuticals Inc has a 12 month low of $4.50 and a 12 month high of $12.30. The company has a quick ratio of 13.95, a current ratio of 14.06 and a debt-to-equity ratio of 14.48. The stock has a market capitalization of $161.11 million, a PE ratio of -1.29 and a beta of 1.52.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.19) by $0.09. Paratek Pharmaceuticals had a negative net margin of 642.70% and a negative return on equity of 232.61%. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.89 million. Analysts expect that Paratek Pharmaceuticals Inc will post -4.53 earnings per share for the current fiscal year.
PRTK has been the topic of a number of recent analyst reports. Canaccord Genuity set a $25.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 18th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. HC Wainwright reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, February 28th. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 1st. Finally, ValuEngine upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $22.25.
ILLEGAL ACTIVITY NOTICE: “Paratek Pharmaceuticals Inc (PRTK) Stake Increased by Water Island Capital LLC” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thelincolnianonline.com/2019/05/15/paratek-pharmaceuticals-inc-prtk-stake-increased-by-water-island-capital-llc.html.
Paratek Pharmaceuticals Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Story: What are catch-up contributions?
Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.